Open Government Portal
Open Data Search has recently undergone significant changes. The search page has moved to search.open.canada.ca/opendata. Please update existing bookmarks accordingly.
Found 10 records similar to Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis
Physical security measures guide for cannabis: Requirements under Part 4 of the Cannabis Regulations
The purpose of this document is to provide guidance to holders of a licence under the Cannabis Act (hereafter referred to as licence holders) on the application of Part 4: Physical Security Measures of the Cannabis Regulations. It is designed to help licence holders understand the physical security requirements for conducting authorized activities with cannabis.
Pursuant to section 56 of the CDSA and subject to the terms and conditions set out herein, applicants for a producer’s licence are exempted from the requirement in paragraph 33(1)(h) to provide a detailed description of security measures determined in accordance with the Security Directive in respect of the storage of cannabis and from the application of paragraph 33(1)(h) of the ACMPR in respect of the proposed security measures that apply in respect of the areas where cannabis plants are cultivated, propagated, harvested or trimmed and to the areas where cannabis seeds are present or stored.
The purpose of this document is to inform stakeholders about the regulatory framework for health products containing cannabis or for use with cannabis that are approved under the Food and Drugs Act. This framework includes requirements for licensed activities, rules that apply to the health products themselves, and obligations for certain healthcare professionals.
Health Canada is issuing this notice to clinical trial sponsors to clarify key obligations under the Food and Drug Regulations (FDR) for various types of cannabis-based clinical research.
Health Canada's interpretation of controlled substances prescribing activities pharmacists can perform under the Controlled Drugs and Substances Act.
Between 2018 and 2020, Health Canada has issued a number of exemptions to the Controlled Drugs and Substances Act. Some of the exemptions have been issued to maintain Canadians' access to controlled substances during the COVID-19 pandemic.
People use substances, such as controlled and illegal drugs, cannabis, tobacco/nicotine and alcohol for different reasons, including: medical purposes, personal enjoyment, religious or ceremonial purposes and to cope with stress, trauma or pain.
On August 24, 2016, Health Canada issued a Section 56 Class Exemption under the Controlled Drugs and Substances Act to enable registered persons under the Access to Cannabis for Medical Purposes Regulations (ACMPR), and individuals responsible for them, to access testing services for dried or fresh marijuana or cannabis oil produced for their own medical purposes.
Health Canada is issuing this Notice to clinical trial sponsors to clarify the approach to various types of clinical research with cannabis.
Health Canada is issuing this Notice to clinical trial sponsors to clarify the approach to various types of clinical research with cannabis.